PMID: 7542357Jul 22, 1995Paper

Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin

Lancet
R R FrenchM J Glennie

Abstract

We report the use of a bispecific F(ab')2 antibody to target the ribosome-inactivating protein saporin to the surface antigen CD22 in the treatment of low-grade, end-stage, B-cell lymphoma. Four patients were treated. Toxic effects were minimal (grade I), with mild fever, weakness, and myalgia for 1-2 days after treatment. One patient showed an antibody response to mouse Fab' and saporin. All patients showed rapid and beneficial responses to treatment with improvements in most disease sites and in peripheral blood cytopenia. The responses were short-lived (less than 28 days) but further study of this targeting system is warranted.

Citations

Jun 6, 2000·Advanced Drug Delivery Reviews·L Zardi, D Neri
Jun 6, 2000·Advanced Drug Delivery Reviews· de Leij LB J Kroesen
Sep 12, 1998·British Journal of Haematology·S SforziniS Ferrini
Nov 10, 2011·Toxins·Letizia PolitoAndrea Bolognesi
Oct 10, 2013·Toxins·Letizia PolitoAndrea Bolognesi
Feb 5, 2003·Advanced Drug Delivery Reviews·Ying Cao, Laura Lam
Apr 15, 1999·Seminars in Cancer Biology·G T Stevenson, M S Cragg
Feb 14, 2018·Toxins·Francesco GiansantiRodolfo Ippoliti
May 26, 2017·Biomedicines·Letizia PolitoMassimo Bortolotti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.